China speaks on GSK bribery charges, and the word isn't good

China is coming down hard on GlaxoSmithKline's ($GSK) local operation. After a months-long bribery probe, Chinese police have slapped Glaxo's former country chief--Mark Reilly, a Brit--and two other top Chinese executives with several counts of bribery. 

The charges are much harsher than industry officials and Chinese insiders had expected. Reilly is accused of actually masterminding an elaborate scheme to bribe doctors to prescribe GSK products. According to police, he ordered Glaxo employees to make secret payments to doctors, hospital staffers and government officials. And the potential penalties are equally harsh: The maximum sentence for a bribery charge in China is life in prison.

One of the big remaining questions is how Glaxo will be penalized. The Financial Times reports that GSK faces "corporate liability," citing an unnamed lawyer close to the company. And Glaxo's own comments aren't comforting, either; the company said it would like to "continue to make an important contribution" to Chinese public health. Which suggests that it might not be allowed to do so. Read more from FiercePharmaMarketing >>

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.